NCT04008069View on ClinicalTrials.gov

Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 3, 2019

Primary Completion Date

July 26, 2022

Study Completion Date

September 9, 2022

Conditions
Sarcoidosis
Interventions
DRUG

Sarilumab

Sarilumab 200 mg administered subcutaneously

DRUG

Placebo

Placebo administered subcutaneously

Trial Locations (1)

94304

Stanford University, Palo Alto

All Listed Sponsors
lead

Stanford University

OTHER

NCT04008069 - Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis | Biotech Hunter | Biotech Hunter